| Information professionnelle sur Cinryze 500 UI, poudre et solvant pour la pr: | Takeda Pharma AG | | | B06AC01 - C1-Inhibitor, Plasma Derived | ATC-DDD Version 2016. Source: WHO | | B - Blood and Blood Forming Organs | | |
| | B06 - Other Hematological Agents | | | No DDDs are established in this group.
|
| | B06A - Other Hematological Agents | This group includes preparations for local and systemic use, and also some preparations used for dissolving clots in catheters, hemodialysis clots etc.
See also:
V07A - All other non-therapeutic products
B01AB - Heparin group
|
| | B06AC - Drugs Used in Hereditary Angioedema | | | The DDD for lanadelumab is based on the starting dose.
|
| | B06AC01 - C1-Inhibitor, Plasma Derived | |
|
|
|
|
